卖什么
Unleash the potential of genomic medicine using AI
商业模式拆解
买家：谁掌握预算？
未核实R&D or business development leadership at biopharma partners (partnership deals).
触发点：什么让他们现在购买？
High early-stage drug R&D failure rates (<10% standard success) and need to de-risk and shorten genomic medicine timelines; claims vision of cutting R&D by 6-7 years.
工作流：什么输入变成什么输出？
In silico prediction of optimal molecular constructs and delivery vectors (e.g. AAV capsids) for a target product profile, validated with external wet labs, delivered as tailored modules.
经济账：省了什么，怎么收费？
未核实Likely partnership, collaboration and milestone-based deals rather than software subscriptions; no pricing shown.
渠道：怎么接触到客户？
Direct partnerships and R&D collaborations with pharma and tech players.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-10-06 | — | $26M | — | news.google.com |
| — | YC 2022 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-17.